<table>
<thead>
<tr>
<th>ICH E3 Guideline Section Number and Title</th>
<th>CORE Reference Section Number and Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Title Page</td>
<td>1 Title Page</td>
</tr>
<tr>
<td>2 Synopsis</td>
<td>2 Synopsis</td>
</tr>
<tr>
<td>3 Table of Contents for the Individual Clinical Study Report</td>
<td>3 Table of Contents</td>
</tr>
<tr>
<td>4 List of Abbreviations and Definition of Terms</td>
<td>4 List of Abbreviations and Definition of Terms</td>
</tr>
<tr>
<td>5 Ethics</td>
<td>5 Ethics</td>
</tr>
<tr>
<td>5.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB)</td>
<td>5.1 Independent Ethics Committee and/or Institutional Review Board</td>
</tr>
<tr>
<td>5.2 Ethical Conduct of the Study</td>
<td>5.2 Ethical Conduct of the Study</td>
</tr>
<tr>
<td>5.3 Patient Information and Consent</td>
<td>5.3 Subject Information and Consent</td>
</tr>
<tr>
<td>6 Investigators and Study Administrative Structure</td>
<td>6 Investigators and Study Administrative Structure</td>
</tr>
<tr>
<td>7 Introduction</td>
<td>7 Introduction</td>
</tr>
<tr>
<td>8 Study Objectives</td>
<td>8 Study Objectives and Endpoints</td>
</tr>
<tr>
<td>9 Investigational Plan</td>
<td>9 Investigational Plan</td>
</tr>
<tr>
<td>9.1 Overall Study Design and Plan - Description</td>
<td>9.1 Overall Study Design and Plan</td>
</tr>
<tr>
<td>9.2 Discussion of Study Design, Including the Choice of Control Groups</td>
<td>9.2 Discussion of Study Design, Including the Choice of Control Groups</td>
</tr>
<tr>
<td>9.3 Selection of Study Population</td>
<td>9.3 Selection of Study Population</td>
</tr>
<tr>
<td>9.3.1 Inclusion Criteria</td>
<td>9.3.1 Inclusion Criteria</td>
</tr>
<tr>
<td>9.3.2 Exclusion Criteria</td>
<td>9.3.2 Exclusion Criteria</td>
</tr>
<tr>
<td>9.3.3 Removal of Patients from Therapy or Assessment</td>
<td>9.3.3 Removal of Subjects from Therapy or Assessment</td>
</tr>
<tr>
<td>9.4 Treatments</td>
<td>9.4 Treatment</td>
</tr>
<tr>
<td>9.4.1 Treatments Administered</td>
<td>9.4.1 Treatments Administered</td>
</tr>
<tr>
<td>9.4.1.1 Investigational Product(s)</td>
<td>9.4.1.1 Investigational Product(s)</td>
</tr>
<tr>
<td>9.4.2 Non-investigational Product(s)</td>
<td>9.4.2 Non-investigational Product(s)</td>
</tr>
<tr>
<td>9.4.2.2 Identity of Investigational Product(s)</td>
<td>9.4.2 Identity of Investigational Product(s)</td>
</tr>
<tr>
<td>9.4.3 Method of Assigning Patients to Treatment Groups</td>
<td>9.4.3 Method of Assigning Subjects to Treatment Groups</td>
</tr>
<tr>
<td>9.4.4 Selection of Doses in the Study</td>
<td>9.4.4 Selection of Dose(s) and Timing of Dose for Each Subject</td>
</tr>
<tr>
<td>9.4.5 Selection and Timing of Dose for each Patient</td>
<td>9.4.5 Selection of Dose(s) and Timing of Dose for Each Subject</td>
</tr>
<tr>
<td>9.4.6 Blinding</td>
<td>9.4.6 Blinding and Unblinding</td>
</tr>
<tr>
<td>9.4.7 Prior and Concomitant Therapy</td>
<td>9.4.7 Prior and Concomitant Therapy</td>
</tr>
<tr>
<td>9.4.8 Treatment Compliance</td>
<td>9.4.8 Treatment Compliance</td>
</tr>
<tr>
<td>9.5 Efficacy and Safety Variables</td>
<td>9.5 Efficacy and Safety Variables</td>
</tr>
<tr>
<td>9.5.1 Efficacy and Safety Measurements Assessed and Schedule of Assessments</td>
<td>9.5.1 Efficacy and Safety Measurements Assessed and Flow Chart</td>
</tr>
<tr>
<td>9.5.4 Drug Concentration Measurements</td>
<td>9.5.4 Drug Concentration Measurements</td>
</tr>
<tr>
<td>9.5.5.1 Pharmacokinetic Measurements</td>
<td>9.5.5.1 Pharmacokinetic Measurements</td>
</tr>
<tr>
<td>9.5.5.2 Pharmacokinetic Parameters</td>
<td>9.5.5.2 Pharmacokinetic Parameters</td>
</tr>
<tr>
<td>9.5.5.3 Pharmacodynamic Parameters</td>
<td>9.5.5.3 Pharmacodynamic Parameters</td>
</tr>
<tr>
<td>9.5.5.4 Pharmacodynamic Parameters</td>
<td>9.5.5.4 Pharmacodynamic Parameters</td>
</tr>
<tr>
<td>9.6 Data quality assurance</td>
<td>9.6 Data Quality Assurance</td>
</tr>
<tr>
<td>9.7 Statistical Methods Planned in the Protocol and Determination of Sample Size</td>
<td>9.7 Statistical Analysis Methods Planned in the Protocol and Determination of Sample Size</td>
</tr>
<tr>
<td>9.7.1 Statistical and Analytical Plans</td>
<td>9.7.1 Statistical Plans</td>
</tr>
<tr>
<td>9.7.2 Determination of Sample Size</td>
<td>9.7.2 Determination of Sample Size</td>
</tr>
<tr>
<td>9.8 Changes in the Conduct of the Study or Planned Analyses</td>
<td>9.8 Changes in the Conduct of the Study or Planned Analyses</td>
</tr>
<tr>
<td>9.8.1 Changes in the Conduct of the Study</td>
<td>9.8.1 Changes in the Conduct of the Study</td>
</tr>
<tr>
<td>9.8.2 Changes in the Planned Analyses</td>
<td>9.8.2 Changes in the Planned Analyses</td>
</tr>
<tr>
<td>9.8.3 Changes Following Study Unblinding and Post-hoc Analyses</td>
<td>9.8.3 Changes Following Study Unblinding and Post-hoc Analyses</td>
</tr>
<tr>
<td>10 Patients</td>
<td>10 Study Subjects</td>
</tr>
<tr>
<td>10.1 Disposition of Patients</td>
<td>10.1 Disposition of Subjects</td>
</tr>
<tr>
<td>10.2 Protocol Deviations</td>
<td>10.2 Protocol Deviations</td>
</tr>
<tr>
<td>11 Efficacy Evaluation</td>
<td>11 Efficacy Evaluation</td>
</tr>
<tr>
<td>11.1 Data Sets Analyzed</td>
<td>10.3 Data Sets Analyzed</td>
</tr>
<tr>
<td>ICH E3 Guideline Section Number and Title</td>
<td>CORE Reference Section Number and Title</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>11.2 Demographic and Other Baseline Characteristics</td>
<td>10.4 Demographic and Other Baseline Characteristics</td>
</tr>
<tr>
<td>11.3 Measurements of Treatment Compliance</td>
<td>10.5 Measurements of Treatment Compliance</td>
</tr>
<tr>
<td>11.4 Efficacy Results and Tabulations of Individual Patient Data</td>
<td>11.1 Efficacy Results</td>
</tr>
<tr>
<td>11.4.1 Analysis of Efficacy</td>
<td>11.1.1 Primary Efficacy Endpoint</td>
</tr>
<tr>
<td>11.4.2 Statistical/Analytical Issues</td>
<td>11.1.2 Secondary Efficacy Endpoints</td>
</tr>
<tr>
<td>11.4.2.1 Adjustments for Covariates</td>
<td>11.1.3 Other Efficacy Endpoints</td>
</tr>
<tr>
<td>11.4.2.2 Handling of Dropouts or Missing Data</td>
<td>11.1.4 Post-hoc Analyses</td>
</tr>
<tr>
<td>11.4.2.3 Interim Analyses and Data Monitoring</td>
<td>11.2 Efficacy Results Summary</td>
</tr>
<tr>
<td>11.4.2.4 Multicentre Studies</td>
<td>12 Safety Evaluation</td>
</tr>
<tr>
<td>11.4.2.5 Multiple Comparison/Multiplicity</td>
<td>12.1 Extent of Exposure</td>
</tr>
<tr>
<td>11.4.2.6 Use of an “Efficacy Subset” of Patients</td>
<td>12.1.1 Brief Summary of Adverse Events</td>
</tr>
<tr>
<td>11.4.2.7 Active-Control Studies Intended to Show Equivalence</td>
<td>12.1.2 Most Frequently Reported Adverse Events</td>
</tr>
<tr>
<td>11.4.2.8 Examination of Subgroups</td>
<td>12.1.3 Categorisation of All Adverse Events</td>
</tr>
<tr>
<td>11.4.3 Tabulation of Individual Response Data</td>
<td>12.2 Analysis of Adverse Events</td>
</tr>
<tr>
<td>11.4.4 Drug Dose, Drug Concentration, and Relationships to Response</td>
<td>12.2.1 Deaths, Other Serious Adverse Events, Discontinuations due to Adverse Events and Other Adverse Events of Special Interest</td>
</tr>
<tr>
<td>11.4.5 Drug-Drug and Drug-Disease Interactions</td>
<td>12.2.1.1 Deaths</td>
</tr>
<tr>
<td>11.4.6 By-Patient Displays</td>
<td>12.2.1.2 Other Serious Adverse Events</td>
</tr>
<tr>
<td>11.4.7 Efficacy Conclusions</td>
<td>12.2.1.3 Other Significant Adverse Events</td>
</tr>
<tr>
<td>12 Safety Evaluation</td>
<td>12.2.1.4 Discontinuations Due to Adverse Events</td>
</tr>
<tr>
<td>12.1 Extent of Exposure</td>
<td>12.2.1.5 Other Adverse Events of Special Interest</td>
</tr>
<tr>
<td>12.1.1 Brief Summary of Adverse Events</td>
<td>12.3 Analysis and Discussion of Deaths, Other Serious Adverse Events, and Other Clinically Meaningful Adverse Events</td>
</tr>
<tr>
<td>12.1.2 Most Frequently Reported Adverse Events</td>
<td>12.3.1 Deaths, Other Serious Adverse Events, and Other Significant Adverse Events</td>
</tr>
<tr>
<td>12.1.3 Categorisation of All Adverse Events</td>
<td>12.3.1.1 Deaths</td>
</tr>
<tr>
<td>12.2 Analysis of Adverse Events</td>
<td>12.3.1.2 Other Serious Adverse Events</td>
</tr>
<tr>
<td>12.2.1 Deaths, Other Serious Adverse Events, Discontinuations due to Adverse Events and Other Adverse Events of Special Interest</td>
<td>12.3.1.3 Other Significant Adverse Events</td>
</tr>
<tr>
<td>12.3.2 Narratives of Deaths, Other Serious Adverse Events, and Certain Other Clinically Meaningful Adverse Events</td>
<td>12.4 Clinical Laboratory Evaluation</td>
</tr>
<tr>
<td>12.4.1 Listing of Individual Laboratory Measurements by Patient</td>
<td>12.3.1 Individual Laboratory Measurements by Subject and Abnormal Laboratory Values</td>
</tr>
<tr>
<td>12.4.2 Evaluation of Each Laboratory Parameter</td>
<td>12.3.2 Evaluation of Laboratory Values</td>
</tr>
<tr>
<td>12.4.2.1 Laboratory Values Over Time</td>
<td>12.3.2.1 Laboratory Values Over Time</td>
</tr>
<tr>
<td>12.4.2.2 Individual Patient Changes</td>
<td>12.3.2.2 Individual Subject Changes in Laboratory Values</td>
</tr>
<tr>
<td>12.4.2.3 Individual Clinically Significant Abnormalities</td>
<td>12.3.2.3 Individual Clinically Meaningful Laboratory Abnormalities</td>
</tr>
<tr>
<td>12.5 Vital Signs, Physical Findings and Other Observations Related to Safety</td>
<td>12.4 Vital Signs, Physical Examinations, and Other Observations Related to Safety</td>
</tr>
<tr>
<td>12.6 Safety Conclusions</td>
<td>12.4.1 Vital Signs</td>
</tr>
<tr>
<td>13 Discussion and Overall Conclusions</td>
<td>12.4.2 Physical Examination Findings</td>
</tr>
<tr>
<td>14 Tables, Figures and Graphs Referred to But Not Included in the Text</td>
<td>12.4.3 Other Observations Related To Safety</td>
</tr>
<tr>
<td>14.1 Demographic Data</td>
<td>13 Discussion and Overall Conclusions</td>
</tr>
<tr>
<td>14.2 Efficacy Data</td>
<td>13.1 Discussion</td>
</tr>
<tr>
<td>14.3 Safety Data</td>
<td>13.2 Conclusions</td>
</tr>
<tr>
<td>14.3.1 Displays of Adverse Events</td>
<td>14 Tables and Figures</td>
</tr>
<tr>
<td>14.3.2 Listings of Deaths, Other Serious and Significant Adverse Events</td>
<td>14.1 Demographic Data</td>
</tr>
<tr>
<td>14.3.3 Listings of Deaths, Other Serious and Clinically Meaningful Adverse Events</td>
<td>14.2 Efficacy Data</td>
</tr>
<tr>
<td>14.3.4 Displays of Adverse Events</td>
<td>14.3 Safety Data</td>
</tr>
<tr>
<td>14.3.5 Listings of Deaths, Other Serious and Clinically Meaningful Adverse Events</td>
<td>14.3.1 Displays of Adverse Events</td>
</tr>
<tr>
<td>NOT INCLUDED</td>
<td>14.3.2 Listings of Deaths, Other Serious and Clinically Meaningful Adverse Events</td>
</tr>
<tr>
<td>ICH E3 Guideline Section Number and Title</td>
<td>CORE Reference Section Number and Title</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>14.3.3 Narratives of Deaths, Other Serious and Certain Other Significant Adverse Events</td>
<td>14.3.3 Narratives of Deaths, Other Serious Adverse Events and Certain Other Clinically Meaningful Adverse Events</td>
</tr>
<tr>
<td>14.3.4 Abnormal Laboratory Value Listing (Each Patient)</td>
<td>14.3.4 Data Listings (Each Subject) for Abnormal Clinically Meaningful Laboratory Values, Vital Signs, Physical Examinations and Other Observations Related to Safety</td>
</tr>
<tr>
<td>15 Reference List</td>
<td>15 Reference List</td>
</tr>
<tr>
<td>16 Appendices</td>
<td>16 Appendices</td>
</tr>
<tr>
<td>16.1 Study Information</td>
<td>16.1 Study Information</td>
</tr>
<tr>
<td>16.1.1 Protocol and protocol amendments</td>
<td>16.1.1 Protocol and protocol amendments</td>
</tr>
<tr>
<td>16.1.2 Sample case report form (unique pages only)</td>
<td>16.1.2 Sample case report form (may include unique pages only)</td>
</tr>
<tr>
<td>16.1.3 List of IECs or IRBs (plus the name of the committee Chair if required by the regulatory authority) – Representative written information for patient and sample consent forms</td>
<td>16.1.3 List of IECs or IRBs (plus the name of the committee Chair if required by the regulatory authority)</td>
</tr>
<tr>
<td>16.1.4 List and description of investigators and other important participants in the study, including brief (1 page) CVs or equivalent summaries of training and experience relevant to the performance of the clinical study</td>
<td>16.1.4 List and description of Investigators and other important participants in the study</td>
</tr>
<tr>
<td>16.1.5 Signatures of principal or coordinating investigator(s) or sponsor’s responsible medical officer, depending on the regulatory authority’s requirement</td>
<td>16.1.5 Signatures of Principal (for single-centre studies) or Coordinating Investigator(s) (for multi-centre studies) and/or Sponsor’s responsible medical officer (depending on the Regulatory Authority’s requirement) and signature of responsible biostatistician</td>
</tr>
<tr>
<td>16.1.6 Listing of patients receiving test drug(s)/investigational product(s) from specific batches, where more than one batch was used</td>
<td>16.1.6 List of Investigational Product(s) batch numbers</td>
</tr>
<tr>
<td>16.1.7 Randomisation scheme and codes (patient identification and treatment assigned)</td>
<td>16.1.7 Randomisation scheme and codes (subject identification and treatment assigned)</td>
</tr>
<tr>
<td>16.1.8 Audit certificates (if available) (see Annex IVa and IVb of the guideline)</td>
<td>16.1.8 Audit certificates (if necessary [region and/or country-specific], and if available)</td>
</tr>
<tr>
<td>16.1.9 Documentation of statistical methods</td>
<td>16.1.9 Documentation of statistical methods</td>
</tr>
<tr>
<td>16.1.10 Documentation of inter-laboratory standardisation methods and quality assurance procedures if used</td>
<td>16.1.10 Documentation of inter-laboratory standardisation methods and laboratory QA procedures if used (depending on the Regulatory Authority’s requirement)</td>
</tr>
<tr>
<td>16.1.11 Publications based on the study</td>
<td>16.1.11 Publications based on study</td>
</tr>
<tr>
<td>16.1.12 Important publications referenced in the report</td>
<td>16.1.12 Important publications referenced in the report</td>
</tr>
<tr>
<td>16.2 Patient Data Listings</td>
<td>16.2 Subject Data Listings</td>
</tr>
<tr>
<td>16.2.1 Discontinued patients</td>
<td>16.2.1 Discontinued Subjects</td>
</tr>
<tr>
<td>16.2.2 Protocol deviations</td>
<td>16.2.2 Protocol Deviations</td>
</tr>
<tr>
<td>16.2.3 Patients excluded from the efficacy analysis</td>
<td>16.2.3 Subjects Excluded from the Efficacy Analysis</td>
</tr>
<tr>
<td>16.2.4 Demographic data</td>
<td>16.2.4 Demographic Data</td>
</tr>
<tr>
<td>16.2.5 Compliance and/or drug concentration data (if available)</td>
<td>16.2.5 Compliance and/or Drug Concentration Data (if available)</td>
</tr>
<tr>
<td>16.2.6 Individual efficacy response data</td>
<td>16.2.6 Individual Efficacy Response Data</td>
</tr>
<tr>
<td>16.2.7 Adverse event listings (each patient)</td>
<td>16.2.7 Adverse Event Listings (each Subject)</td>
</tr>
<tr>
<td>16.2.8 Listing of individual laboratory measurements by patient, when required by regulatory authorities</td>
<td>16.2.8 Listing of Individual Laboratory Measurements by Subject When Required by Regulatory Authorities</td>
</tr>
<tr>
<td>16.3 Case Report Forms</td>
<td>16.3 Case Report Forms</td>
</tr>
<tr>
<td>16.3.1 CRFs for deaths, other serious adverse events and withdrawals for AE</td>
<td>16.3.1 CRFs for deaths, other SAEs and withdrawals for AE</td>
</tr>
<tr>
<td>16.3.2 Other CRFs submitted</td>
<td>16.3.2 Other CRFs submitted (only if applicable)</td>
</tr>
<tr>
<td>16.4 Individual Patient Data Listings (US Archival Listings)</td>
<td>16.4 Individual Subject Data Listings (US archival listings)</td>
</tr>
<tr>
<td>ANNEX I Synopsis (Example)</td>
<td>NOT INCLUDED - Example synopsis table is included in Section 2 (Synopsis) of the CORE Reference (so Annex I Synopsis is removed from annexes)</td>
</tr>
<tr>
<td>ANNEX II Principal or Coordinating Investigator(s) Signature(s) or Sponsor’s Responsible Medical Officer (Example)</td>
<td>ANNEX I (Appendix 16.1.5) Principal or Coordinating Investigator(s) Signature(s) (and/or Sponsor’s Responsible Medical Officer Signature and Statistician’s Signature)</td>
</tr>
<tr>
<td>ANNEX IIIa Study Design and Schedule of Assessments (Example)</td>
<td>NOT INCLUDED - Example Table 9.1 (9.5.1 Efficacy and Safety Measurements Assessed and Schedule of Assessments) in the CORE Reference is derived from Annexes IIIa and IIIb (which are therefore removed from the annexes)</td>
</tr>
<tr>
<td>ANNEX IIIb Study Design and Schedule of Assessments (Example)</td>
<td>NOT INCLUDED - Example Table 9.1 (9.5.1 Efficacy and Safety Measurements Assessed and Schedule of Assessments) in the CORE Reference is derived from Annexes IIIa and IIIb (which are therefore removed from the annexes)</td>
</tr>
<tr>
<td>ANNEX IVa Disposition of Patients (Example)</td>
<td>NOT INCLUDED - Example Figure 10.1 in the CORE Reference (Section 10.1 Disposition of Patients) is derived and amended from Annexes IVa and IVb (which are therefore removed from annexes)</td>
</tr>
<tr>
<td>ANNEX IVb Disposition of Patients (Example)</td>
<td>NOT INCLUDED - Example Figure 10.1 in the CORE Reference (Section 10.1 Disposition of Patients) is derived and amended from Annexes IVa and IVb (which are therefore removed from annexes)</td>
</tr>
<tr>
<td>ICH E3 Guideline Section Number and Title</td>
<td>CORE Reference Section Number and Title</td>
</tr>
<tr>
<td>------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>ANNEX V Listing of Patients Who Discontinued Therapy (Example)</td>
<td>ANNEX II (Appendix 16.2.1) Listing of Subjects Who Discontinued Treatment (Data Set Identification)</td>
</tr>
<tr>
<td>ANNEX VI Listing of Patients and Observations Excluded from Efficacy Analysis</td>
<td>ANNEX III (Appendix 16.2.3) Listing of Subjects and Observations Excluded from the Efficacy Analysis</td>
</tr>
<tr>
<td>ANNEX VII Number of Patients Excluded from Efficacy Analysis (Example)</td>
<td>NOT INCLUDED - Example Table 10.2 in the CORE Reference (Section 10.2 Protocol Deviations) is derived and amended from Annex VII (which is therefore removed from annexes)</td>
</tr>
<tr>
<td>ANNEX VIII Guidance for Section 11.4.2 – Statistical/Analytical Issues and Appendix 16.1.9</td>
<td>ANNEX IV Guidance for Sections 9.7 and 11.2 - Statistical Issues and Appendix 16.1.9</td>
</tr>
</tbody>
</table>

New

9.3.4 Stopping or Suspending the Study
9.4.3 Avoidance of Bias
9.5.1.2 Secondary Efficacy Measurements
9.5.1.3 Other Efficacy Measurements
11.3 Pharmacokinetic, Pharmacodynamic and Other Analyses Results
11.3.3 Other Endpoints
14.4 Other Data
16.1.13 Optional Appendix e.g. Data Monitoring Committee
ANNEX V (Appendix 16.2.7) Adverse Events: Number Observed and Rate, With Subject Identifications
ANNEX VI (all measurements in Listing 16.2.8; abnormal measurements in Listing 14.3.3)